Of all the skin-care and cosmetics products I recently bought online that turned out to be counterfeit, expired, used, or otherwise problematic, the one that still makes me squirm ...

Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that ...

The big O. The climax. The explosive finale. For men, this almost always involves ejaculation. But guys, have you ever wondered how much semen you’re actually meant to produce when you orgasm? It’s a ...

(The Hill) – Homeland Security Secretary Kristi Noem confirmed on Sunday that the agency is conducting an internal review of the actions taken by the Immigration and Customs Enforcement (ICE) officer ...

It's official: this is Taylor Swift's Eras Tour lip combo. For many of us, longevity is a non-negotiable requirement when it comes to lip makeup. We need formulas that can keep up with our hectic ...

KANSAS CITY, Mo. (KCTV) - A change will impact some Black Friday shoppers this year. It’s one that many people out looking for deals won’t have considered before hitting the checkout line. Business ...

Abbott made a takeover offer for Exact Sciences. The two companies want to team up to combat cancer. Under the terms of the deal, Exact Sciences' stockholders would receive $105 per share in cash. The ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

In January, Exact Sciences CEO Kevin Conroy told us that 2025 was shaping up to be a transformative year for the diagnostics company. Three cancer test launches, multiple study readouts and one $23 ...